Opinions Brad Willock
Laboratory Corp. of American HoldingsLHTOP PICKDec 11, 2006
Clinical testing lab. About 40% of US tests by doctors go to either this or Quest Diagnostics (DGX-N). With an aging population, there is more testing giving more revenue. Very predictable, high cash flow driven model.
Brad WillockOwned
$72.38
Stock price when the opinion was issued
$322.59
As of Aug 13, 2026. Market Open.
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
TOP PICK
Clinical research and testing for drug companies. They have really good visibility of growth ahead of it. (Analysts’ target: $155.00).
Andy NasrOwned
biotechnologypharmaceutical
TOP PICK
Clinical labs. 2 big players own most of the market. Expects volume will increase because of aging population needing more and more tests. Very profitable.
Brad WillockOwned
biotechnologypharmaceutical
